Future Tech: Almost Here, Round-the-corner Future Technology Podcast

Quantgene combines deep genomics with AI to detect cancer very early. When you listen, you'll hear Mr. Bhakdi explain: What information they are able to glean from a blood test regarding cancer presence. The difference and benefit of a "liquid biopsy" or blood test compared with a conventional tumor biopsy. How this test is able to recognize mutational expressions despite the heterogeneity of most tumors. Quantgene founder and CEO Jo Bhakdi discusses the company's focus on early cancer detection through blood testing to find its earliest markers. With a human genome sequence software-driven technology that also engages chemistry, machine learning, and laboratory processes, Quantgene is able to sequence and investigate cancer DNA one by one. This increases the accuracy and speed by an exponential degree compared to other detections that were based on protein marker identification. The test can pick up somatic DNA mutations in the blood caused by tumors with a whole new level of precision by detecting